FIBROMYALGIA research has reached a major milestone as a multi-ancestry meta-analysis of over 2.5 million individuals identified 26 Fibromyalgia Genetic Loci, establishing the condition’s neuro-genetic framework. Evaluating 54,629 cases and 2,509,126 controls across 11 international cohorts, the investigation provides robust biological evidence defining fibromyalgia as a central nervous system disorder. These findings support the central sensitization model, wherein altered neural processing leads to heightened pain sensitivity, hyperalgesia, and widespread musculoskeletal discomfort.
The strongest single-variant association mapped to a coding variant in exon 58 of the Huntingtin gene (HTT), conferring a 9 percent increase in disease odds. Beyond HTT, gene prioritization implicated GPR52, a known regulator of HTT, along with several candidate genes involved in synaptic plasticity, neuronal development, and nociceptors, including DCC, DRD2/NCAM1, MDGA2, and CELF4. Tissue enrichment analysis demonstrated that heritability was exclusively localized to central nervous system structures, specifically the cortex, caudate, putamen, and anterior cingulate cortex. Cell-type analyses further reinforced this neural architecture, demonstrating peak enrichment in hippocampal dentate gyrus neurons and enteric neurons.
Phenome-wide association testing revealed extensive pleiotropy and shared genetic architecture between fibromyalgia and various somatic and psychiatric conditions. Genetic correlations exceeded 0.70 for major pain syndromes, post-traumatic stress disorder, and irritable bowel syndrome. Conversely, genetic overlap with autoimmune disorders was modest, aligning more closely with seronegative rheumatoid arthritis than seropositive subtypes. Notably, while females accounted for nearly 88 percent of diagnosed cases, the common-variant genetic architecture was identical between sexes, indicating that clinical prevalence disparities reflect non-genetic factors or diagnostic biases. Polygenic risk scoring effectively stratified patient disease risk, while identified loci such as GPR52 and CELF4 suggest novel targets for therapeutic development. Ultimately, identifying these 26 risk loci provides a concrete biological foundation to shift the clinical paradigm toward targeted, centrally mediated pain management strategies.
Reference
Kerrebijn I et al. The genetic architecture of fibromyalgia across 2.5 million individuals. Nat Med. 2026.
Featured Image: amenic181 Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
